Navigation Links
Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Date:8/14/2014

REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira® in healthy subjects.  The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined, PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first to last time point measured (AUC0-t), and area under the time-concentration curve from first time point extrapolated to infinity (AUC0-inf), with all three geometric mean ratios fully within the 90% confidence interval from 80% to 125%.  Both agents were well tolerated and there were no differential safety findings observed between the two agents in this study.

"An essential global regulatory requirement is the completion of a clinical study directly comparing the originator and our biosimilar candidate establishing PK similarity," said Barbara Finck, M.D., Chief Medical Officer of Coherus. "We are pleased to have achieved robust results which we believe represents a significant reduction in development program risk."

"Adalimumab is a very complex molecule. Achieving this clinical milestone further validates Coherus' development platform and demonstrates our ability to advance biosimilars across our portfolio," said Denny Lanfear, President and Chief Executive Officer of Coherus.

About Coherus BioSciences, Inc.
Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market.  Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience
'/>"/>

SOURCE Coherus BioSciences
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Coherus anuncia início do estudo Fase 3 do CHS-0214 (Biossimilar Investigativo do Etanercept) em psoríase crônica em placas (RaPsOdy)
2. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
3. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
4. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
5. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
6. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
7. Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update
8. Edison Nation Medical Announces Innovation Search To Improve Hazardous Waste Disposal in Hospitals & Healthcare Facilities
9. NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES
10. Vermillion Announces Additions to Commercial Management Team
11. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Varian Medical Systems (NYSE: VAR ... the fourth quarter of fiscal year 2014 following the ... The news release will be followed by a teleconference ... The news release and a link to the conference ... at: www.varian.com/investor .  To access the teleconference call ...
(Date:10/1/2014)... 2014 Quantum Materials Corp (OTCQB:QTMM) today ... photoactive quantum dots for use in next-generation ... advantages for solar power generation, the high cost ... dots with which to develop thin film solar ... utilization and acceptance. The company is also seeking ...
(Date:10/1/2014)... , Oct. 1, 2014 ... a clinical-stage biopharmaceutical company focused on cardio-renal, ... results from its 371 patient Phase 2b ... constipation-predominant irritable bowel syndrome (IBS-C).  Results from ... meaningful improvement in IBS-C symptoms for tenapanor-treated ...
Breaking Medicine Technology:Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... EAST RUTHERFORD, N.J., Oct. 20 Cambrex Corporation (NYSE: ... Silver Innovation Award at the 2009 CPhI Event for ... award was accepted by Dr. Jayne E. Muir (Market ... technology to a panel of judges at this important ...
... 20 Abaxis, Inc. (Nasdaq: ABAX ), a medical ... conference call to discuss its financial results for the second ... call will be at 4:15 p.m. ET on Tuesday, October ... 858-4600 to access the conference call, or can listen via ...
Cached Medicine Technology:Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award 2Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009 2
(Date:10/1/2014)... (October 1, 2014) Despite a policy focus ... developmental disabilities, this vulnerable population continues to have ... The Journal of the American Dental Association ... and Tufts University School of Dental Medicine report ... influencing at-home oral care provided by caregivers to ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... DURHAM, N.C. A new genetic finding from Duke ... hostility, anxiety and depression might also be hard-wired to ... diabetes and heart disease. , An estimated 13 percent ... the genetic susceptibility, and knowing this could help them ... healthy diet, exercise and stress management. , "Genetic susceptibility, ...
(Date:10/1/2014)... NJ (PRWEB) October 01, 2014 Diet Doc ... their intentions to lose weight and their dieting attempts could ... fatty foods. Including hormone diet treatments into their ... allows patients to see fast and effective weight loss results, ... begin forming healthy habits to maintain their weight for the ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... , TUESDAY, Nov. 22 (HealthDay News) -- ,Taking ... by the brand name Tylenol) over time can lead to ... to a new study. These "staggered overdoses" can occur ... more acetaminophen than they should, explained Dr. Kenneth Simpson, author ...
... HealthDay Reporter , TUESDAY, Nov. 22 (HealthDay News) -- As ... related health problems, a new study finds. In 2009, ... reactions to beverages such as Monster and Rockstar than they ... released Tuesday. More than 13,000 ER visits related to ...
... -- Elderly black patients who require surgery for an intestinal ... the hospital than white patients, a new study has found. ... black patients had the same health insurance as white patients, ... pouches in the lining of the intestine become infected or ...
... Langone Medical Center researchers have discovered the novel protective ... study, published in the November issue of journal ... against acute pancreatitis, a sudden dangerous swelling and inflammation ... demonstrate that an abundance of dendritic cells are needed ...
... Nov. 22 (HealthDay News) --,College students tend to smoke when ... study. "Students are using social events and work as ... author, Nikole Cronk, an assistant professor of family and community ... a news release. "This research is important for those working ...
... News) -- A weakened immune system and unhealthy lifestyle habits ... cancer, according to a new study. The researchers also ... HIV infection might reduce cancer risk. The primary goal ... risk of cancer in HIV-infected patients, was to determine how ...
Cached Medicine News:Health News:Too Much Acetaminophen Over Time May Damage Liver 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 2Health News:ER Visits for Energy-Drink Ills Soar in U.S. 3Health News:More Blacks Die in Hospital After Diverticulitis Surgery 2Health News:Dendritic cells protect against acute pancreatitis 2Health News:Dendritic cells protect against acute pancreatitis 3Health News:College Students Smoke When They Party, Drink and Work 2Health News:HIV Patients at Heightened Risk for Certain Cancers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: